GlucoTrack Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Erik Emerson

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	1.8yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 10

GlucoTrack to start R&D program for glucose monitoring system

GlucoTrack (NASDAQ:GCTK) said it will begin a new R&D program for a long-term continuous glucose monitor to expand its product pipeline. Following a recent acquisition of certain related IP, GlucoTrack intends to develop a long-term implantable glucose management technology to address the Type 1 diabetes market, the company said in an Oct. 10 press release. GlucoTrack said it previously reported that it completed lab testing of its non-invasive GlucoTrack 2.0 clinical prototype system and saw better-than-expected accuracy and performance with the technology. The company is scheduled to begin its first-in-human trials later this quarter.

CEO

Erik Emerson (55 yo)

no data

Tenure

Mr. Erik C. Emerson is CEO & Director of Lokahi Therapeutics Inc. Mr. Emerson is CEO & Director of GlucoTrack, Inc. from July 14, 2026. Mr. Emerson was appointed Chief Executive Officer of Lokahi Therapeut...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Paul Goode	Chief Technical Officer & President	no data	US$394.10k	0.0054% $ 169.6
Erik Emerson	CEO & Director	no data	no data	no data
Avner Gal	Co-Founder	25.5yrs	US$187.39k	no data
David Malka	Co-Founder	25.5yrs	US$199.35k	no data
Vincent Wong	Chief Operations Officer	1.3yrs	no data	0.000020% $ 0.6
Mark Tapsak	Chief Scientific Officer	1.3yrs	US$176.21k	no data
Drinda Benjamin	Chief Commercial Officer	less than a year	no data	no data

1.3yrs

Average Tenure

57.5yo

Average Age

Experienced Management: GCTK's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Erik Emerson	CEO & Director	no data	no data	no data
Avner Gal	Co-Founder	9.3yrs	US$187.39k	no data
Andrew Balo	Independent Director	2.1yrs	US$114.00k	0.075% $ 2.3k
Luis Malave	Independent Chairman	5.1yrs	US$134.00k	0.065% $ 2.0k
David Klonoff	Chair of Scientific Advisory Board	5.3yrs	no data	no data
Erin Carter	Independent Director	2.9yrs	US$114.00k	0.034% $ 1.1k
Victoria Carr-Brendel	Independent Director	1.2yrs	US$74.83k	0.0069% $ 216.9
Guillermo Umpierrez	Chair of Medical Advisory Board	1.4yrs	no data	no data
Usman Latif	Member of Clinical Advisory Board	less than a year	no data	no data
David Hirsh	Clinical & Scientific Advisor	less than a year	no data	no data

1.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: GCTK's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/17 13:31
End of Day Share Price	2026/07/17 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GlucoTrack, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

GlucoTrack Management

Management criteria checks 0/4

Key information

Recent management updates

Glucotrack, Inc. and Lokahi Therapeutics Announces Executive Appointments to Its Combined Company

High number of new and inexperienced directors

Glucotrack, Inc. Appoints Usman Latif to its Clinical Advisory Team

Glucotrack, Inc. Appoints David S. Hirsh, MD as Medical Director, Cardiology

Glucotrack, Inc. Approves the Election of Victoria Carr-Brendel as Director

GlucoTrack, Inc., Annual General Meeting, May 22, 2025

Recent updates

Lokahi Therapeutics Inc. entered into an Agreement and Plan of Merger to acquire GlucoTrack, Inc. (NasdaqCM:GCTK) in a reverse merger transaction.

Glucotrack, Inc. and Lokahi Therapeutics Announces Executive Appointments to Its Combined Company

Glucotrack Inc Highlights Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association 2026 Scientific Sessions

New major risk - Negative shareholders equity

Glucotrack, Inc. Receives Nasdaq Notice for Failure to Comply with the Minimum Stockholders’ Equity Requirement

Glucotrack Inc Announces Peer-Reviewed Study Supporting Long-Life Sensor Design For Implantable Continuous Blood Glucose Monitoring Technology

High number of new and inexperienced directors

New major risk - Financial position

Glucotrack Inc Files Significant Ide with Fda for Us Clinical Trial in Early Second Quarter Based on Critical 2025 Milestones

New major risk - Share price stability

GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $3.999997 million.

New major risk - Financial position

Glucotrack, Inc. Appoints Usman Latif to its Clinical Advisory Team

GlucoTrack, Inc. announced that it has received $3 million in funding

GlucoTrack, Inc. announced that it expects to receive $20 million in funding from Sixth Borough Capital Management, LP.

Glucotrack, Inc. Appoints David S. Hirsh, MD as Medical Director, Cardiology

Glucotrack, Inc. and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor At American Diabetes Association's 85Th Scientific Sessions

Glucotrack, Inc. Approves the Election of Victoria Carr-Brendel as Director

New major risk - Financial position

Glucotrack, Inc. Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor

GlucoTrack, Inc., Annual General Meeting, May 22, 2025

Nasdaq Determines to Delist GlucoTrack Securities Due to Non-Compliance with Bid Price Rule

Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member

GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $3.033748 million.

Glucotrack, Inc. Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor

GlucoTrack Announces Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Price Requirement

GlucoTrack, Inc. Announces Chief Financial Officer Changes

GlucoTrack, Inc. Receives Nasdaq Non-Compliance Letter Regarding Bid Price Rule

GlucoTrack, Inc. has filed a Follow-on Equity Offering in the amount of $8.23 million.

GlucoTrack, Inc. Announces Start of Enrollment for Human Clinical Study of Continuous Blood Glucose Monitor

GlucoTrack, Inc. has completed a Follow-on Equity Offering in the amount of $9.995237 million.

Glucotrack, Inc. Appoints John Ballantyne to Its Board of Directors

GlucoTrack, Inc. announced that it has received $0.1 million in funding

Glucotrack Announces the Appointment of Andy Balo to Board of Directors

Glucotrack Reports Successful Completion of First Reported Long-Term Preclinical Study of Its Epidural Glucose Monitoring Sensor

Glucotrack, Inc Announces 90-Day Preclinical Study Results That Demonstrate Sustained Accuracy of Its Implantable Continuous Blood Glucose Monitor

GlucoTrack Receives a Third Letter from Nasdaq Notifies Not Regains Compliance with the Minimum Bid Price Requirement During the Extended Compliance Period

Glucotrack’s Epidural Glucose Monitoring Sensor Demonstrates Successful 30-Day Safety & Performance in Long-Term Preclinical Study

Glucotrack Announces Reverse Stock Split to Regain Compliance with the $1.00 Minimum Bid Price Requirement

GlucoTrack, Inc. announced that it has received $0.5 million in funding

GlucoTrack, Inc. Announces Expansion of its Continues Glucose Monitoring Technology to Epidural Glucose Monitoring

Glucotrack Announces Increased Sensor Longevity for Its Implantable Continuous Blood Glucose Monitor

GlucoTrack, Inc., Annual General Meeting, Apr 26, 2024

Glucotrack, Inc Announces Appointment of Luis Malavé as Chairman of Its Board of Directors

GlucoTrack, Inc. Announces Early Accuracy Data for its Implantable Continuous Glucose Monitor

GlucoTrack, Inc. Announces Executive Changes

Glucotrack, Inc. Appoints Erin Carter to Its Board of Directors and as Chair of Its Audit Committee

Glucotrack, Inc. Announces Positive Data from Feasibility Study for Implantable Continuous Glucose Monitor

GlucoTrack Receives Letter from Nasdaq Regarding No Longer Complies with Nasdaq's Listing Rule 5550(a)(2)

Nasdaq Issues a Letter to GlucoTrack Granting an Extension Until May 22, 2023 to Obtain Compliance

Glucotrack to Begin Research & Development of Novel Continuous Glucose Monitoring System

GlucoTrack to start R&D program for glucose monitoring system

GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor

Shalom Shushan, Chief Technology Officer, Provides Notice of His Resignation from Glucotrack, Inc., Effective May 22, 2022

Integrity Applications, Inc. announced delayed 10-Q filing

Integrity Applications, Inc. announced delayed annual 10-K filing

Integrity Applications, Inc. Announces Executive Changes

Integrity Applications Appoints Paul V. Goode to Board of Directors

Integrity Applications, Inc. Appoints Shalom Shushan as Chief Technology Officer, Effective November 9, 2020

Integrity Applications, Inc. Announces Resignation of Eugene Naidis as Vice President of R&D, Effective December 31, 2020

CEO

Leadership Team

Board Members

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources